Literature DB >> 10565888

Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and vitek YBC systems.

A C Gales1, M A Pfaller, A K Houston, S Joly, D J Sullivan, D C Coleman, D R Soll.   

Abstract

To have a better understanding of the role of Candida dubliniensis in clinical infections, it is essential that microbiology laboratories can identify this species rapidly and accurately in clinical specimens. C. dubliniensis has been reported to lack the ability to utilize xylose (XYL) and alpha-methyl-D-glucoside (MDG) and to grow poorly or not at all at 45 degrees C, whereas Candida albicans isolates utilize XYL and MDG and usually grow well at 45 degrees C. We tested 66 isolates of C. dubliniensis and 100 isolates of C. albicans with both the API 20C AUX and Vitek YBC systems to evaluate the ability of the XYL and MDG tests contained within each of these systems to distinguish between the two species. The ability to grow at 45 degrees C was also examined. None of the C. dubliniensis isolates grew at 45 degrees C, and 23 of 100 C. albicans isolates (23%) exhibited poor or no growth at 45 degrees C. The XYL and MDG tests contained within the API 20C AUX system were both negative for all 66 C. dubliniensis isolates and were positive for 98 (XYL) and 56 (MDG) of the 100 C. albicans isolates. With the Vitek system, 64 of 66 C. dubliniensis isolates (97.0%) were XYL negative and 63 (95.0%) were MDG negative. Conversely, 96 of 100 C. albicans isolates (96.0%) were XYL positive and 100 (100.0%) were MDG positive with the Vitek system. Clinical microbiology laboratories could use lack of growth at 45 degrees C and a negative XYL test with either the API 20C AUX or Vitek yeast identification system to provide a presumptive identification of C. dubliniensis. A negative MDG test result with either system would also be helpful but may misclassify C. albicans as C. dubliniensis, especially when the API 20C AUX system is used.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565888      PMCID: PMC85818     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

Review 1.  Candidiasis: the emergence of a novel species, Candida dubliniensis.

Authors:  D C Coleman; D J Sullivan; D E Bennett; G P Moran; H J Barry; D B Shanley
Journal:  AIDS       Date:  1997-04       Impact factor: 4.177

2.  Evaluation of the modified API 20C system for identification of clinically important yeasts.

Authors:  W J Buesching; K Kurek; G D Roberts
Journal:  J Clin Microbiol       Date:  1979-05       Impact factor: 5.948

3.  Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.

Authors:  G P Moran; D J Sullivan; M C Henman; C E McCreary; B J Harrington; D B Shanley; D C Coleman
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals.

Authors:  D Sullivan; K Haynes; J Bille; P Boerlin; L Rodero; S Lloyd; M Henman; D Coleman
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

Review 5.  Fungal infections in patients with acquired immunodeficiency syndrome.

Authors:  G Y Minamoto; A S Rosenberg
Journal:  Med Clin North Am       Date:  1997-03       Impact factor: 5.456

6.  Development and characterization of complex DNA fingerprinting probes for the infectious yeast Candida dubliniensis.

Authors:  S Joly; C Pujol; M Rysz; K Vargas; D R Soll
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation.

Authors:  J F Meis; M Ruhnke; B E De Pauw; F C Odds; W Siegert; P E Verweij
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

8.  Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals.

Authors:  D J Sullivan; T J Westerneng; K A Haynes; D E Bennett; D C Coleman
Journal:  Microbiology       Date:  1995-07       Impact factor: 2.777

Review 9.  Epidemiology and control of fungal infections.

Authors:  M A Pfaller
Journal:  Clin Infect Dis       Date:  1994-08       Impact factor: 9.079

Review 10.  Importance of Candida species other than C. albicans as pathogens in oncology patients.

Authors:  J R Wingard
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

View more
  34 in total

Review 1.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates.

Authors:  Somanon Bhattacharya; Jack D Sobel; Theodore C White
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.

Authors:  Preeti Pancholi; Steven Park; David Perlin; Christine Kubin; Phyllis Della-Latta
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

4.  Prevalence of Candida dubliniensis fungemia in Argentina: identification by a novel multiplex PCR and comparison of different phenotypic methods.

Authors:  Maria Eugenia Bosco-Borgeat; Constanza Giselle Taverna; Susana Cordoba; Maria Guillermina Isla; Omar Alejandro Murisengo; Wanda Szusz; Walter Vivot; Graciela Davel
Journal:  Mycopathologia       Date:  2011-07-13       Impact factor: 2.574

5.  Rapid identification and differentiation of Candida albicans and Candida dubliniensis by capillary-based amplification and fluorescent probe hybridization.

Authors:  Rangaraj Selvarangan; Ajit P Limaye; Brad T Cookson
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Detection, identification, and distribution of fungi in bronchoalveolar lavage specimens by use of multilocus PCR coupled with electrospray ionization/mass spectrometry.

Authors:  Jeong Hwan Shin; Raymond Ranken; Susan E Sefers; Robert Lovari; Criziel D Quinn; Shufang Meng; Heather E Carolan; Donna Toleno; Haijing Li; Jeong Nyeo Lee; Charles W Stratton; Christian Massire; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2012-10-24       Impact factor: 5.948

7.  The usefulness of DNA sequencing after extraction by Whatman FTA filter matrix technology and phenotypic tests for differentiation of Candida albicans and Candida dubliniensis.

Authors:  Nuri Kiraz; Yasemin Oz; Huseyin Aslan; Hamza Muslumanoglu
Journal:  Mycopathologia       Date:  2014-01-17       Impact factor: 2.574

8.  Candida dubliniensis at a university hospital in Saudi Arabia.

Authors:  R Fotedar; S S A Al-Hedaithy
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Candida albicans and non-C. albicans Candida species: comparison of biofilm production and metabolic activity in biofilms, and putative virulence properties of isolates from hospital environments and infections.

Authors:  A V Ferreira; C G Prado; R R Carvalho; K S T Dias; A L T Dias
Journal:  Mycopathologia       Date:  2013-03-27       Impact factor: 2.574

10.  Environmental source of Candida dubliniensis.

Authors:  Miles A Nunn; Stefanie M Schäefer; Michael A Petrou; Jillian R M Brown
Journal:  Emerg Infect Dis       Date:  2007-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.